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Umbilical cord blood has become a viable and widely used alternative stem cell source 
for patients with hematologic diseases in need of hematopoietic cell transplant (1-4). 
Several studies have reported comparable survival rates for adult cord blood transplant 
(CBT) recipients when compared to unrelated donor (URD) peripheral blood or bone 
marrow transplantation [5-6]. Moreover, Brunstein et al.  recently reported a lower rate 
of relapse among double CBT recipients than patients who received either matched or 
mismatched URD transplants [7]. The vast majority of CBT recipients receive highly 
HLA-mismatched grafts which may contribute to the lower incidence of relapse. 
Interestingly, a recent study suggests maternal cells in CB grafts that are sensitized to 
fetal inherited paternal antigens (IPAs) [Figure 1] may also contribute to the lower 
incidence of relapse [8].   
Fetal exposure to noninherited maternal HLA antigens (NIMA) [Figure 2] is thought to 
produce tolerance to NIMA, and improved outcome was previously reported when NIMA 
of the CB donor was shared by a recipient [9]. On the other hand, during pregnancy 
women develop B- and T-cell immunity against fetal histocompatibility antigens (HLA) 
and minor histocompatibility antigens that are paternally-inherited.  Although CB grafts 
consist primarily of fetal cells, some maternal cells are present [10,11].  Indirect 
evidence reported by van Rood and colleagues strongly implicates maternal immune 
cells with anti-IPA activity in the graft versus leukemia (GVL) effect observed with CBT. 
Maternal cells are implicated because relapse was reduced specifically when the 
transplant recipient had one or more HLA antigens that were the same as an IPA of the 
CB donor [8].  The study included patients with hematological malignancies (n=1155) 
who were transplanted with a single CB unit from the New York Cord Blood Bank 
between 1993 and 2006. The majority of patients (n=1030) shared one or more HLA 
antigens with CB IPAs and had at least 1, 2 or 3 HLA-A, -B, -DRB1 mismatches. No 
differences, with respect to total nucleated cell dose and patient characteristics, were 
seen between no-shared IPA (n=64) and shared IPA transplants. Interestingly, the risk 
of relapse within the first 3 years was significantly lower among the patients with 
shared-IPA than those that with no shared-IPA. The risk reduction was stronger in 
patients who received CBT that had one HLA mismatch. In this group of patients lower 
relapse risk was associated with a lower risk of treatment failure, although without 
significant improvement in overall survival.  
Of note, van Rood et al. also showed that the risk of relapse was lower when the CB 
unit came from a later birth order versus a first birth, further supporting a role of 
maternal exposure to fetal paternally-inherited HLA-antigens. In addition, when HLA 
mismatch of the mother and the CBT recipient was considered in a multivariate model, 
the association between shared-IPA and relapse risk reduction remained significant. 
The latter analysis confirmed that the GVL effect could not be attributed to maternal 
mismatch but was putatively due to maternal cells with anti-IPA activity. The price to pay 
for increased GVL activity was a slightly higher risk of acute grade III-IV graft-versus-
host-disease (GVHD) among patients with shared IPAs.  However, GVHD incidence 
was only significant in patients with 2 HLA mismatches, and not significant in patients 
with only 1 HLA mismatch.  
This important work brings a new perspective to the way we think of the immunological 
potential of CBT.  The anti-leukemia activity of CB grafts is likely due at least in part to 
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maternal immune cells contained within the graft conferring a potent GVL effect. 
However, this indirect evidence needs now to be followed by specific work that identifies 
and characterizes the type of maternal cells in CB and the mechanism of action for the 
observed GVL effect. From a practical standpoint, the evaluation of IPA match in CB 
selection can be considered at the time a CB donor search is initiated. Although the 
majority of patients will share one or more antigen with CB IPAs, the benefit of knowing 
IPAs along with NIMA is likely to improve CB unit selection and consequently to 
significantly enhance the efficacy of CBT for patients with hematological malignancies. 
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Figure  2.  Decreased  transplant  related  mortality  was  reported  in  an  earlier  paper  (9)  for  patients 
receiving one or two antigen mismatched cord blood transplants when the patient had  the same HLA 
antigen as the CB’s NIMA.   
 
Example: NIMA Effect 
Patient  08  07 
 
 CB unit   08  35 
Mother  of  CB unit   08  07 
 
Patient and Donor CB unit are mismatched at the B locus: patient has B*07 while CB has B*35. However, 
the patient’s mismatched B*07 matches the CB’s NIMA at the same locus.  
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